IDEAYA BIOSCIENCES INC (IDYA) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:IDYA • US45166A1025

34.155 USD
+0.09 (+0.28%)
Last: Feb 3, 2026, 11:44 AM
Fundamental Rating

4

Overall IDYA gets a fundamental rating of 4 out of 10. We evaluated IDYA against 524 industry peers in the Biotechnology industry. While IDYA has a great health rating, there are worries on its profitability. While showing a medium growth rate, IDYA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • IDYA had negative earnings in the past year.
  • IDYA had a negative operating cash flow in the past year.
  • In the past 5 years IDYA always reported negative net income.
  • In the past 5 years IDYA reported 4 times negative operating cash flow.
IDYA Yearly Net Income VS EBIT VS OCF VS FCFIDYA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

  • With an excellent Return On Assets value of -13.52%, IDYA belongs to the best of the industry, outperforming 81.11% of the companies in the same industry.
  • IDYA's Return On Equity of -14.67% is amongst the best of the industry. IDYA outperforms 86.07% of its industry peers.
Industry RankSector Rank
ROA -13.52%
ROE -14.67%
ROIC N/A
ROA(3y)-18.98%
ROA(5y)-16.31%
ROE(3y)-20.3%
ROE(5y)-18.96%
ROIC(3y)N/A
ROIC(5y)N/A
IDYA Yearly ROA, ROE, ROICIDYA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for IDYA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IDYA Yearly Profit, Operating, Gross MarginsIDYA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

8

2. Health

2.1 Basic Checks

  • IDYA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, IDYA has more shares outstanding
  • IDYA has more shares outstanding than it did 5 years ago.
  • IDYA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IDYA Yearly Shares OutstandingIDYA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IDYA Yearly Total Debt VS Total AssetsIDYA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 18.82 indicates that IDYA is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of IDYA (18.82) is better than 88.36% of its industry peers.
  • IDYA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 18.82
ROIC/WACCN/A
WACC8.9%
IDYA Yearly LT Debt VS Equity VS FCFIDYA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M 1B

2.3 Liquidity

  • IDYA has a Current Ratio of 12.44. This indicates that IDYA is financially healthy and has no problem in meeting its short term obligations.
  • IDYA has a better Current ratio (12.44) than 87.40% of its industry peers.
  • IDYA has a Quick Ratio of 12.44. This indicates that IDYA is financially healthy and has no problem in meeting its short term obligations.
  • IDYA has a better Quick ratio (12.44) than 87.40% of its industry peers.
Industry RankSector Rank
Current Ratio 12.44
Quick Ratio 12.44
IDYA Yearly Current Assets VS Current LiabilitesIDYA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

  • IDYA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.17%, which is quite impressive.
  • IDYA shows a strong growth in Revenue. In the last year, the Revenue has grown by 5377.66%.
  • The Revenue for IDYA have been decreasing by -36.96% on average. This is quite bad
EPS 1Y (TTM)20.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%321.67%
Revenue 1Y (TTM)5377.66%
Revenue growth 3Y-36.96%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • IDYA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.85% yearly.
  • The Revenue is expected to grow by 157.91% on average over the next years. This is a very strong growth
EPS Next Y56.82%
EPS Next 2Y-5.32%
EPS Next 3Y-2.85%
EPS Next 5Y11.85%
Revenue Next Year4195.55%
Revenue Next 2Y238.95%
Revenue Next 3Y185.4%
Revenue Next 5Y157.91%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IDYA Yearly Revenue VS EstimatesIDYA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
IDYA Yearly EPS VS EstimatesIDYA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IDYA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IDYA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IDYA Price Earnings VS Forward Price EarningsIDYA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IDYA Per share dataIDYA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • A cheap valuation may be justified as IDYA's earnings are expected to decrease with -2.85% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.32%
EPS Next 3Y-2.85%

More info and screens

0

5. Dividend

5.1 Amount

  • IDYA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

IDEAYA BIOSCIENCES INC

NASDAQ:IDYA (2/3/2026, 11:44:36 AM)

34.155

+0.09 (+0.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)02-11
Inst Owners110.21%
Inst Owner Change-1.1%
Ins Owners0.9%
Ins Owner Change0%
Market Cap2.99B
Revenue(TTM)214.83M
Net Income(TTM)-160.25M
Analysts84.8
Price Target50.7 (48.44%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)165.01%
Min EPS beat(2)-9.31%
Max EPS beat(2)339.34%
EPS beat(4)1
Avg EPS beat(4)45.05%
Min EPS beat(4)-128.31%
Max EPS beat(4)339.34%
EPS beat(8)2
Avg EPS beat(8)19.11%
EPS beat(12)6
Avg EPS beat(12)16.57%
EPS beat(16)8
Avg EPS beat(16)16.42%
Revenue beat(2)1
Avg Revenue beat(2)1929.23%
Min Revenue beat(2)-100%
Max Revenue beat(2)3958.47%
Revenue beat(4)2
Avg Revenue beat(4)951.38%
Min Revenue beat(4)-100%
Max Revenue beat(4)3958.47%
Revenue beat(8)2
Avg Revenue beat(8)431.13%
Revenue beat(12)4
Avg Revenue beat(12)283.7%
Revenue beat(16)6
Avg Revenue beat(16)239.05%
PT rev (1m)0.16%
PT rev (3m)4.1%
EPS NQ rev (1m)-1.98%
EPS NQ rev (3m)-13.48%
EPS NY rev (1m)0.03%
EPS NY rev (3m)55.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)10.79%
Revenue NY rev (1m)0.93%
Revenue NY rev (3m)1366.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.94
P/FCF N/A
P/OCF N/A
P/B 2.74
P/tB 2.74
EV/EBITDA N/A
EPS(TTM)-1.86
EYN/A
EPS(NY)-3.66
Fwd EYN/A
FCF(TTM)-1.2
FCFYN/A
OCF(TTM)-1.17
OCFYN/A
SpS2.45
BVpS12.46
TBVpS12.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.52%
ROE -14.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-18.98%
ROA(5y)-16.31%
ROE(3y)-20.3%
ROE(5y)-18.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 122.97%
Cap/Sales 1.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.44
Quick Ratio 12.44
Altman-Z 18.82
F-Score5
WACC8.9%
ROIC/WACCN/A
Cap/Depr(3y)140.34%
Cap/Depr(5y)121.83%
Cap/Sales(3y)23.99%
Cap/Sales(5y)16.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%321.67%
EPS Next Y56.82%
EPS Next 2Y-5.32%
EPS Next 3Y-2.85%
EPS Next 5Y11.85%
Revenue 1Y (TTM)5377.66%
Revenue growth 3Y-36.96%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year4195.55%
Revenue Next 2Y238.95%
Revenue Next 3Y185.4%
Revenue Next 5Y157.91%
EBIT growth 1Y7.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year37.2%
EBIT Next 3Y-13.92%
EBIT Next 5YN/A
FCF growth 1Y9.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.96%
OCF growth 3YN/A
OCF growth 5YN/A

IDEAYA BIOSCIENCES INC / IDYA FAQ

What is the fundamental rating for IDYA stock?

ChartMill assigns a fundamental rating of 4 / 10 to IDYA.


Can you provide the valuation status for IDEAYA BIOSCIENCES INC?

ChartMill assigns a valuation rating of 0 / 10 to IDEAYA BIOSCIENCES INC (IDYA). This can be considered as Overvalued.


Can you provide the profitability details for IDEAYA BIOSCIENCES INC?

IDEAYA BIOSCIENCES INC (IDYA) has a profitability rating of 2 / 10.


What is the earnings growth outlook for IDEAYA BIOSCIENCES INC?

The Earnings per Share (EPS) of IDEAYA BIOSCIENCES INC (IDYA) is expected to grow by 56.82% in the next year.